Comparative study of the synergistic effect of Iso Surbide Di Nitrate on standard medical treatment in acute urinary retention compared to current standard treatment alone

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170417033489N5

Enrollment

Registered

2020-05-08

Start date

2019-05-22

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BENIGN PROSTATE HYPERPLASIA. Enlarged prostate

Interventions

Intervention 1: Intervention group: In addition to standard alpha-blocker ( capsule Tamsulosin 0.4 mg Daily ) and antiandrogen ( tablet Finastride 5 mg Daily )therapyy, 10 mg of isosorbide dinitrate i

Eligibility

Sex/Gender

Male

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient has acute urinary retention He is over 50 years old. Has experienced the first episode of urinary retention Is not undergoing another treatment or has no indication for surgery The patient's urinary retention is due to the presence of BPH

Exclusion criteria

Exclusion criteria: History of any heart, liver, kidney, metabolic disease and seizures Fever in the patient means T more than 38 degrees Celsius High PSA (above 4) or suspicious examination that casts doubt on prostate cancer Secondary urinary retention in other cases such as neurogenic bladder

Design outcomes

Primary

Measure	Time frame
Percentage of patients discharged from the urinary catheter. Timepoint: 21 DAYS. Method of measurement: Lack of urinary retention following urinary catheter removal.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Soltani

Mashhad University of Medical Sciences

soltanis@mums.ac.ir+98 51 3802 2553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026